Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. (Q45735869)
Jump to navigation
Jump to search
scientific article published in March 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. |
scientific article published in March 2008 |
Statements
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO (English)
Barbara Schmalfeldt
Guelten Oskay-Oezcelik
Dominique Koensgen
Hans-Joachim Hindenburg
Peter Klare
Werner Lichtenegger
Radoslav Chekerov
Salah-Eddin Al-Batran
Ulf Neumann
Jalid Sehouli
Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO)